Aligos Therapeutics (NASDAQ:ALGS) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report sent to investors on Friday, Benzinga reports. They currently have a $75.00 price target on the stock.

Aligos Therapeutics Price Performance

ALGS stock opened at $8.10 on Friday. The company’s 50-day moving average is $13.09 and its 200-day moving average is $16.08. Aligos Therapeutics has a 1 year low of $7.80 and a 1 year high of $30.00. The stock has a market capitalization of $632.69 million, a PE ratio of -6.33 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The firm had revenue of $1.06 million during the quarter. During the same quarter in the prior year, the firm earned ($10.75) EPS. On average, analysts anticipate that Aligos Therapeutics will post -8.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds have recently bought and sold shares of ALGS. Armistice Capital LLC grew its stake in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the period. Acadian Asset Management LLC boosted its stake in Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares during the last quarter. Opaleye Management Inc. raised its holdings in shares of Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares during the period. Finally, Altitude Crest Partners Inc. purchased a new position in Aligos Therapeutics in the fourth quarter valued at approximately $1,889,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).